Company intelligence / Profile preview
Shaanxi Aoxing Pharmaceutical
Shaanxi, China
- Ownership
- Private
- Employees
- ~230
- Development stage
- Other
01
Overview
Shaanxi Aoxing Pharmaceutical has a pivotal Phase 2 trial ongoing for utidelone injection plus capecitabine in HER2-negative breast cancer patients with brain metastases, with a demonstrated ability to cross the blood-brain barrier and plans to expand studies to other brain tumors.
- Therapeutic areas
- OncologyNeurologyOther
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Biostar Pharmaceuticals (parent)
Beyond the preview
Go deeper on Shaanxi Aoxing Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shaanxi Aoxing Pharmaceutical.